A conserved epitope III on hepatitis C virus E2 protein has alternate conformations facilitating cell binding or virus neutralization

Lu Deng, Nancy Hernandez, Lilin Zhong, David D. Holcomb, Hailing Yan, Maria Luisa Virata, Sreya Tarafdar, Yanqun Xu, Yong He, Evi Struble, Harvey J. Alter, and Pei Zhang

The E2 protein has long been regarded as the primary neutralization target for antibodies that can effectively block HCV entry. By solving the atomic structure of epitope III (524–529 APTYSW) (18), we identified mutations that can alter the conformation of the epitope to favor antibody recognition rather than CD81 binding. These findings should help to design strategies to control HCV infection by tipping the balance toward epitope III conformations that favor antibody recognition rather than CD81 binding.

Significance

Epitope III, a segment on the E2 glycoprotein of the hepatitis C virus (HCV) which binds to the host receptor CD81, is a key target for antibodies to block HCV entry. By solving the atomic structure of epitope III bound to a site-specific neutralizing antibody, mAb1H8, we showed that the epitope can adopt two distinct conformations by moving the side chains of its amino acids, allowing it to bind with either mAb1H8 or CD81. The existence of different conformational states of epitope III suggests its possible role in the regulation of antibody responses. These findings should help to design strategies to control HCV infection by tipping the balance toward epitope III conformations that favor antibody recognition rather than CD81 binding.

Author contributions: P.Z. designed research; L.D., N.H., L.Z., D.D.H., H.Y., M.L.V., S.T., Y.X., and Y.H. performed research; L.D., N.H., D.D.H., E.S., and H.J.A. contributed new reagents/analytic tools; L.D., N.H., D.D.H., M.L.V., and H.J.A. analyzed data; and L.D., M.L.V., H.L.A., and P.Z. wrote the paper.

Reviewers: H.E.B., University Hospital Freiburg; and S.-L.L., The Ohio State University. The authors declare no competing interest.

This open access article is distributed under Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND).

1To whom correspondence may be addressed. Email: halter@dtm.cc.nih.gov or pei.zhang@fda.hhs.gov.

Published July 6, 2021.
Trp529 were among the most critical residues in the E2 protein for stable structure and were dispensable for the antibody binding. C-terminal residues between positions 531 and 534 were not visible N-terminal residues between positions 520 and 522 and the four the electron-density map without ambiguity. However, the three III peptide between positions 523 and 530 were modeled into the binding groove of the Fab region. Eight residues in the epitope (CDRs) of the antibody were well-defined in the complex struc- of the complex.

peptide was mixed with the Fab of mAb1H8 for the crystallization genotype 1 E2 protein sequence was chemically synthesized to peptide (520DRSGAPTYSWGANDK 534) based on the HCV was then demonstrated in an in vitro cell-based infection assay (18). After intentionally immunizing mice with a nearly full-length version mAb1H8 was capable of selecting epitope III in a relatively rigid epitope III. 

Overview of the Epitope III–mAb1H8 Complex Structure. Our postulation that the epitope III residues form different interfaces for engaging its partners during HCV infections prompted us to determine the crystal structure of epitope III. To minimize the possibility of inducible binding of the epitope peptides, we used an epitope III site-specific antibody, mAb1H8, to capture the conforma- tion of the epitope. We chose mAb1H8 because it was generated after intentionally immunizing mice with a nearly full-length version of the E2 protein of the HCV H77 strain. Its neutralizing activity was then demonstrated in an in vitro cell-based infection assay (18). To embody the functional characteristics of epitope III, a 15-mer peptide (²²DPRSGAPTYSWGANDK³³) based on the HCV genotype 1 E2 protein sequence was chemically synthesized to contain most of the amino acids of the CD81-binding loop, wherein epitope III (APTYSW) was precisely mapped. The synthesized peptide was mixed with the Fab of mAb1H8 for the crystallization of the complex.

As shown in Fig. 1, all the complementarity-determining regions (CDRs) of the antibody were well-defined in the complex struc- ture. The electron density of the peptide was clearly observed in the binding groove of the Fab region. Eight residues in the epitope III peptide between positions 523 and 530 were modeled into the electron-density map without ambiguity. However, the three N-terminal residues between positions 520 and 522 and the four C-terminal residues between positions 531 and 534 were not visible in the complex, suggesting that these seven residues did not form a stable structure and were dispensable for the antibody binding.

Description of the Epitope III–mAb1H8 Interface. Our previous analysis indicated that the epitope III residues Ala²²⁴, Pro²²⁵, Tyr²²⁷, and Trp²²⁹ were among the most critical residues in the E2 protein for binding by mAb1H8 (18). In this epitope III–mAb1H8 structure, each of these epitope residues was found to be deeply buried in the complex (Fig. 1A). Noticeably, the residue Ala²²⁴, along with its neighbor, Gly²²³, was involved in contacting the residues in CDR3 of the heavy chain and CDR2 of the light chain, and encircled by the bulky side chains of Arg³¹ and Tyr²³ of the light chain, where the methyl group on the alanine was confined within a cavity by van der Waals forces (Fig. 1B). The tightness between the epitope and the antibody at the site of Ala²²⁴ suggested that any replacement of Ala²²⁴ by an amino acid with a larger side chain, such as valine, would lead to a steric clash with the antibody (Fig. 1C). This structural feature correlated well with the fact that the mutation of Ala²²⁴ by a valine significantly reduced the binding of mAb1H8 to the E2 protein (18). As noted in our previous survey of the frequency at which an alanine is located at position 524 of the E2 protein, Val²²⁴ exists in ~48% of all the HCV E2 protein sequences de- posited in the National Institute of Allergy and Infectious Diseases Virus Pathogen Database and Analysis Resource (https://www. viprbrc.org/brc/home.spg?decorator=vipr) (18). The sequences with Val²²⁴ could thus represent the natural variants with a potential to escape in the presence of epitope III–specific antibodies, while maintaining their infectivity.

Of the four C-terminal residues in epitope III, the pair of Tyr²²⁷ and Trp²²⁹ has been linked to the folded structure of the E2 protein (18, 23–25). Mutation of either one of them could reduce the interaction between the E2 protein and CD81, although some of the reported conformational antibodies have reacted differently to these mutations (24). In the context of mAb1H8, both residues made multiple contacts with the CDR loops by forming a hydrogen-bond network between their side chains and the acidic residues Asp³¹ and Glu³⁶ on the heavy chain (Fig. 1A). The tight interactions, along with the high shape complementarity, between these two aromatic bulky residues and mAb1H8 make any substitutions less tolerable, thus sup- porting a “lock and key” mode of action. By contrast, Ser²³⁸, which appeared in 27% of natural variants of epitope III and is frequently replaced by Thr (20%) or Asn (43%) (18), interacted predominantly with the CDR loops of the light chain (Fig. 1A).

Epitope residue Pro²²⁵ was found to contact loosely with CDR1 and CDR2 on the light chain of the antibody (Fig. 1A). This structural feature is somewhat contrary to the observed fragility of antibody response to the presumed shape changes in recognizing the epitope with a Pro²²⁵→Ala mutation (18). However, since Pro²²⁵ is extremely conserved among all HCV strains, a Pro²²⁵→Ala mutant could not represent one of the natural variants for the virus to escape from epitope III–specific antibodies. Interestingly, a Pro²²⁵→Ala mutation did not affect the CD81–E2 interaction. The highly conserved Pro²²⁵ may simply function as a locus for upholding the rigid structure in the E2 protein. Similarly, Thr²³⁶, another highly conserved epitope residue, was positioned in a relatively spacious binding pocket (Fig. 1A), which enabled the antibody to have a certain degree of freedom to accept different amino acids at this site. This result was consistent with the observation that the Thr²³⁶→Ala mutation of epitope III had little, if any, effect on the mAb1H8 binding to the E2 protein, although it severely weakened the E2–CD81 interaction (18). These results suggest to us that mAb1H8 was capable of selecting epitope III in a relatively rigid form and, in turn, neutralized the virus by locking the epitope in a defined conformation.

Fig. 1. Interactions between epitope III and mAb1H8. The antibody heavy chain is shown in magenta, the light chain in orange, and epitope III in yellow. (A) Key contacts between mAb1H8 and epitope III. (B) Surface representation of mAb1H8 and epitope III showing the tight fit between the side chains of Arg³¹ and Tyr²³ of the mAb1H8 light chain and Ala²²⁴ of epitope III. (C) Potential steric clash between Val²²⁴ of the epitope III variant (in green) and Tyr²³ of the mAb1H8 light chain.

An Alternate Conformation of Epitope III. We asked whether the conformation of epitope III varies while the epitope is free from binding by a site-specific antibody. To answer this question, we examined the epitope structures that were previously reported in the context of various forms of E2 complexed with a variety of antibodies (23, 26, 27). Since epitope III was located farther away from the reported antibody binding sites, we inferred that the
conformations of epitope III in these E2 structures represent unbound forms of the epitope.

Epitope III, when isolated from these E2 structures, showed a very similar shape. However, epitope III, when bound by mAb1H8, was found to be distinct (Fig. 2A). The rmsd was calculated in the range of 2.1 to 2.4 Å. The contours generated by the three N-terminal residues (Ala524, Pro525, and Thr526) under both conditions were superimposable; however, the side chains of Tyr527, Ser528, and Trp529 at the C terminus in the presence of mAb1H8 projected toward different directions from those in the absence of mAb1H8, with respect to the axial reference assumed by the skein 524APT526 (Fig. 2B and C).

To further determine whether the conformation identified in this study represented a novel form of epitope III, Protein Data Bank (PDB) sequences were aligned against the sequence of the E2 ectodomain (23, 26, 27), and the atomic coordinates for the segment aligning with epitope III “APTYSWG” were extracted to generate an rmsd clustering heatmap by using the SVDSuperimposer package in the Biopython library. We found that epitope III in the complex with mAb1H8 had a unique conformation relative to all other E2 structures (Fig. 3A). Noticeably, epitope III was found to be clustered with both PDB ID codes 4WEB and 4WMF against all other E2 structures. Additionally, although epitope III was clustered with PDB ID codes 4WMF and 4WEB for structural similarity, it was clustered with the other E2 structures for sequence similarity. These observations allowed us to conclude that the structural uniqueness was not merely due to sequence differences (Fig. 3B).

Given the unique properties of epitope III, we asked whether mAb1H8 could recognize the epitope III conformations of the other E2 structures described in the PDB. Since all the known E2 structures adopted a similar scaffold, the E2 ectodomain complexed with a neutralizing antibody, HEPC74 (PDB ID code 6MEH), was chosen as a model for our further analysis (Fig. 4). When the epitope III–mAb1H8 complex structure was mounted onto the E2 structures by aligning the common epitope III sequence, all six CDR loops of mAb1H8 were found to interfere with multiple parts of E2 in the current E2 conformations, indicating that steric clashes would occur to prevent mAb1H8 from binding to E2. Therefore, E2 is likely to adopt an alternate conformation when it is bound by mAb1H8, implying that a conformational transition is required for E2 to be recognized by mAb1H8.

Epitope III Conformational State-Specific for CD81 Interaction. In light of the different roles of individual residues of epitope III in their selective engagement with mAb1H8 and CD81, we asked if epitope III, when it is not occupied by an antibody, as it was seen in the E2 core, could shift its residues into a specific conformation suitable for CD81 binding.

Previously, we showed that Tyr527 and Trp529 in epitope III are critical for CD81 binding and that Ala524, Pro525, and Ser528 are replaceable without disturbing the CD81 binding (18). Because Ser528 in epitope III is interchangeable with asparagine or threonine in the natural HCV variants, we tested Asn528 and Thr528, substituted peptides, assuming they take the same conformation displayed on the E2 structure, to see if they could dock onto the crystal structure of the human CD81 large extracellular domain (CD81-LEL) by using the Rosetta FastRelax protocols (Fig. 5). We found that all these peptides upheld the low-energy backbone and side-chain conformations with a nearly identical side-chain orientation that could dock equally onto a single motif on CD81-LEL, specifically the d-helix. These results were in line with our finding that the E2 variant with a Ser528-Ala substitution did not affect the CD81 binding (18).

To test whether the epitope III peptide could be physically associated with peptides containing the d helix of CD81-LEL, we performed random peptide phage display–screening experiments using the epitope III peptides as bait (Table 1). As Ala524 of epitope III was irrelevant to CD81 binding, it was purposely removed from the epitope peptides. In addition, because Ser528 was interchangeable with Asn528 in the natural variants without an impact on CD81 binding, two separate peptides, namely the S peptide (PTYSWGGSSGS) and the N peptide (PTYNWSGGSSGS), containing Ser528 and Asn528, respectively, were thus included in this experiment. We found several phage-displayed peptides that mimicked the “d helix” (i.e., 182ISNLFKE188), particularly at the residue positions Ser183 and Asn184. In addition, Lys187 and Glu188 of the d helix could be replaced by similar types of amino acids, arginine and aspartic acid, respectively, despite varying their linear positions in these “CD81-like” peptide mimics (Table 1). This result provided experimental evidence, as predicted by our computational simulation, that the epitope III peptide could present an alternate conformation suitable for CD81 interaction in the absence of a site-specific antibody, such as mAb1H8.

Fig. 2. Comparison of epitope III conformations from different complex structures. (A) Superimposition of epitope III currently available in the PDB onto the mAb1H8-bound form of epitope III. The PDB ID codes from which the coordinates of epitope III were extracted are 6URH, 6MEH, 6MEK, 6ME1, 6ME2, 6WO3, 6WO4, 6WOQ, 6UYM, 6UYD, 6UYG, 6UYF, 4MWF, 6KBK, 6KBK, and 6BKC. (A and B) Side-chain projections of alternate epitope III conformations identified in the presence of mAb1H8 (B) or in the absence of mAb1H8 (C). Pro525 serves as a central point of the epitope, in conjunction with Ala524 and Thr526, forming an axis of reference for the trajectories of the side chains of Tyr527, Ser528, and Trp529.
Discussion

Protein is not a static object; instead, it is populated by a dynamic ensemble of various conformational states. The interconversions of these conformations, operating often in a variety of space and time scales, govern the different functions of the protein (28). In the case of HCV, the E2 protein is anticipated to be flexible, even though its core structure appears to be well-maintained by its intramolecular chemical bonds (26, 29–32). One of the consequences of such structural flexibility is the increased probability of the virus to prevent the host immune system from generating site-specific antibodies that can effectively neutralize the virus. In this study, we have presented a line of evidence to suggest that epitope III in the context of the E2 protein is no exception in this respect.

With mAb1H8, an antibody that binds specifically to epitope III and is able to neutralize the virus, we were able to capture the epitope in a conformational state that is different from those described previously regarding the CD81-binding loop of the HCV E2 structure. These conformational states of epitope III are linked with the subtle movements of the side chains in the C-terminal residues of the epitope, while the structural rigidity associated with the N-terminal residues is well-preserved. Consequently, the two resulting conformers exhibit distinct abilities in choosing their binding partners, either the antibody mAb1H8 or the host cell entry factor CD81.

The coexistence of two distinct forms of epitope III indicates a possibility of conformational equilibrium that may be established locally on the HCV E2 protein. If this is the case, the likelihood of each conformer occurring could be determined, in theory, by the relative free energies of these E2 conformers and, likewise, the rate of interconversion between them by the energy barrier of side-chain movements. However, the driving force for triggering this conformational transition remains to be investigated.

The conformational alternation as observed locally at epitope III cannot be viewed as an independent affair from other conformational deviations occurring at different regions on the E2 protein. More likely, each of these local conformational changes acts in accordance with maintaining a dynamic equilibrium globally at the level of the E2 protein. The different activities of the E2 protein are thus expected to correspond to discrete structures.
instance, the functionally related epitope II (437WLAGLF442) is hidden in the aforementioned E2 structures with some of its residues protruding into the cavity formed by the CD81-binding loop (21, 23). Despite epitope II being concealed, epitope II site-specific antibodies are still able to neutralize the virus, presumably by relying on the conformational changes occurring in E2 that can expose the epitope for antibody binding (20, 30, 33). To support this dynamic view, a recent study has uncovered the existence of an alternate conformer of E2 with its descriptive “neutralizing face” composed of the CD81-binding loop and the front layer of E2 (25).

According to the distributions of populated conformers, our findings may help to interpret the relationship between HCV infection and host immune defense. The dominance of conformers that are recognized by the epitope III residue-specific antibodies may skew antibody response toward virus neutralization. Conversely, the dominance of CD81-specific conformers could presumably increase the probability for the virus to enter liver cells, thus facilitating viral infections while avoiding antibody binding. Relevant to this interpretation, we previously showed that the antibodies with a specificity toward the epitope III residues could be produced in less than 15% of patients only when the chronic HCV infection had already been established (18). While this observation suggests an inadequate production of antibodies to epitope III during natural HCV infection, it raises the question of whether the conformational equilibrium plays a role in determining an antibody response in these patients.

It should be pointed out that a naturally occurring variant of epitope III, the Ala524→Val substitution, where a larger side chain is introduced, is no longer structurally induced, with the binding pocket of mAb1H8. However, this epitope variant still retains its full capacity to bind CD81 (18). The appearance of Ala524 and Val524 variants reflects the selection pressure imposed by site-specific neutralizing antibodies that drives sequence evolution at epitope III during natural HCV infections, a general concept supported by several studies (34, 35). The highly conserved epitope III sequence not only stabilizes the epitope at specific positions, such as Tyr527 and Trp529, for the structural rigidity needed for one function but also permits the subtle flexibility in the side chains, as seen in this case, for the other function.

These observations allow us to conclude that there are two independent mechanisms operating jointly at epitope III: The variation at specific positions, such as Ala524→Val, offers a survival advantage for the virus under the selective pressure of the site-specific antibodies and, simultaneously, the high conservation of other epitope amino acids, such as Tyr527 and Trp529, ensures the ability of the virus to preserve local conformational dynamics for ultimately modulating antibody responses and viral entry during infection. From uncovering these structural insights, our findings should help researchers design future experiments to test whether HCV infection could be controlled by tipping the balance of epitope III conformations to favor recognition by neutralizing antibodies.

**Materials and Methods**

**Peptide Synthesis and Protein Preparation.** All peptides were chemically synthesized by the Core Laboratory of the Center for Biologics Evaluation and Research at the US Food and Drug Administration, by using an Applied Biosystems model 433A peptide synthesizer as previously described (22, 33).

S peptide: PTYWGGSGGS-biotin

N peptide: PTYNWGGSGGS-biotin

| Peptide Synthesis and Protein Preparation. | | |
|---|---|---|
| All peptides were chemically synthesized by the Core Laboratory of the Center for Biologics Evaluation and Research at the US Food and Drug Administration, by using an Applied Biosystems model 433A peptide synthesizer as previously described (22, 33). | | |

**Crystallization and Data Collection.** Crystallization screenings were carried out robotically with a Mosquito liquid dispenser from SPT LabTech by the hanging-drop vapor-diffusion method (33). Crystals of the epitope III–mAb1H8 complex were grown in 20% polyethylene glycol 3350, 0.1 M citrate (pH 5.5) at 21 °C. Glycerol (20% volume/volume) was used as the cryoprotectant. X-ray diffraction data were collected at beamline X29 of the Brookhaven National Synchrotron Light Source with an ADSC Quantum-315 charge-coupled device detector. All data were indexed, integrated, and scaled with the program HKL2000 (36).

**Structure Determination and Refinement.** The structure of the epitope III–mAb1H8 complex was determined as previously described (33) by molecular replacement using Phaser (37) in CCP4 (38) with the anti-HCV epitope II antibody mAb8 (PDB ID code 4H1Z) as the search model (33). After refinement with RefMac 5.0 (39), the epitope III peptide was built into the resulting structure.

**Table 1. Identification of CD81-like peptides by screening random peptide phage display libraries**

| Epitope III peptide | Phage-displayed peptide | Residue similarity to those of CD81 (d helix 182NFKL188) |
|---|---|---|
| N peptide | ITNAPIKDLTP | N182, S183, S184, N186, K187, E188 |
| | N5SNDFRRGGPET | S183, N184, S186, K187, E188 |
| S peptide | SNNKNDTRILTK | S183, N184, E186, E188 |

N peptide: PTYNWGGSGGS-biotin; S peptide: PTYSWGSSGSGS-biotin. Underline: amino acids identified that are similar or identical to the d helix.

**Fig. 5.** Rosetta docking of the E2 structure with CD81. Three conformations of the epitope III peptide variants with the residues 525PTYN (S, T) W529 restrained as observed in the E2 core structure are docked to the d helix of CD81-LEL (PDB ID code 5DFV). Residues of the epitope III peptide and CD81-LEL are shown in stick representation. Backbone and side-chain atoms of epitope III are indicated in yellow. The altered residues (Asn528, Thr528, and Ser528) in the epitope are shown in red, magenta, and pink.
difference electron-density map using the program Coot (40). The CDR loops were deleted in the initial refinement and built into where an unambiguous electron density was shown. There were two complexes in a crystallographic asymmetric unit with nearly identical conformations as indicated by the r.m.s.d of 0.2 Å in the α-carbon atoms of the variable domain of the Fab molecules and the epitope III peptides. Contact residues in the epitope III–mAb1H8 complex were identified with the program Contact in CCP4 and were defined as residues containing an atom ≤4.0 Å from a residue of the binding partner. Buried surface areas were calculated by the program AreMaol in CCP4 with a 1.4-Å probe radius. PyMOL (https://pymol.org/2/) was used to prepare the structural figures.

Rosetta Docking of the HCV E2 Structure with Human CD81. The crystal structure of HCV E2 protein (PDB ID code 4MWF) was used as a docking partner to human CD81 (PDB ID code SDVF). The Rosetta Docking Protocol was implemented in ROSIE (Rosetta Online Server; https://rosseta.graylab.jhu.edu) to allow for the identification of possible binding sites (41–43). Manual inspection was then performed on the top-scoring structures.

Computational Analysis of Peptides with Rosetta FastRelax. The Rosetta FastRelax protocol (all-atom refinement) was performed on the docked structure of the PDB ID code 6MEH E2 sequence using Clustal Omega (47, 48). For the final refinement and built into where an unambiguous electron density was shown. There were two complexes in a crystallographic asymmetric unit with nearly identical conformations as indicated by the r.m.s.d of 0.2 Å in the α-carbon atoms of the variable domain of the Fab molecules and the epitope III peptides. Contact residues in the epitope III–mAb1H8 complex were identified with the program Contact in CCP4 and were defined as residues containing an atom ≤4.0 Å from a residue of the binding partner. Buried surface areas were calculated by the program AreMaol in CCP4 with a 1.4-Å probe radius. PyMOL (https://pymol.org/2/) was used to prepare the structural figures.

alignment of epitope III conformations contained in the pdb. the e2 sequence was taken from pdb id code 6meh (26). this sequence was queried against the protein data bank (46) using default values, and all matching structures were downloaded. for each matching structure, all chains were aligned with the pdb id code 6meh e2 sequence using clustal omega (47, 48). for the closest matching chain, atomic coordinates for the subsequence aligned to aptyswg were extracted. the substitution for the e2 sequence. the substitution for the e2 sequence. the substitution for the e2 sequence. this was determined from the DNA sequence. the sequence homology of phage-displayed peptides with CD81-LEL was determined. the epitope-binding peptides with a high sequence homology to the CD81-LEL sequence were defined as CD81-like peptides.

Data Availability. The atomic coordinates and structure factors reported in this article have been deposited in the Protein Data Bank, https://www.wwpdb.org/ (PDB ID code 7LKL). All study data are included in the main text.

ACKNOWLEDGMENTS. We thank Howard Robinson at the Brookhaven National Synchrotron Light Source for X-ray data collection. Beamline X29 is supported by the US Department of Energy Offices of Biological and Environmental Research and Basic Energy Sciences and by the National Center for Research Resources of the NIH. This study used the computational resources of the High Performance Computing clusters at the Food and Drug Administration (FDA), Center for Devices and Radiological Health (CDRH). This study was funded by intramural research funds from the Center for Biologics Evaluation and Research (CBER). FDA. S.T. was supported by the Research Participation Program at the CBER, administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the US Department of Energy and the FDA.
32. A. D. Dearborn, J. Marcotrigiano, Hepatitis C virus structure: Defined by what it is not. Cold Spring Harb. Perspect. Med. 10, a036822 (2020).
33. L. Deng et al., Structural evidence for a bifurcated mode of action in the antibody-mediated neutralization of hepatitis C virus. Proc. Natl. Acad. Sci. U.S.A. 110, 7418–7422 (2013).
34. K. A. Dowd, D. M. Netski, X. H. Wang, A. L. Cox, S. C. Ray, Selection pressure from neutralizing antibodies drives sequence evolution during acute infection with hepatitis C virus. Gastroenterology 136, 2377–2386 (2009).
35. T. von Hahn et al., Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Gastroenterology 136, 2377–2386 (2009).
36. Z. Otwinowski, W. Minor, Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276, 307–326 (1997).
37. L. C. Storoni, A. J. McCoy, R. J. Read, Likelihood-enhanced fast rotation functions. Acta Crystallogr. D Biol. Crystallogr. 60, 432–438 (2004).
38. Collaborative Computational Project, Number 4, The CCP4 suite: Programs for protein crystallography. Acta Crystallogr. D Biol. Crystallogr. 50, 760–763 (1994).
39. G. N. Murshudov, A. A. Vagin, E. J. Dodson, Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D Biol. Crystallogr. 53, 240–255 (1997).
40. P. Emsley, B. Lohkamp, W. G. Scott, K. Cowtan, Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486–501 (2010).
41. S. Chaudhury et al., Benchmarking and analysis of protein docking performance in Rosetta v3.2. PLoS One 6, e22477 (2011).
42. S. Lyskov et al., Serverification of molecular modeling applications: The Rosetta online server that includes everyone (ROSETIE). PLoS One 8, e63906 (2013).
43. S. Lyskov, J. J. Gray, The RosettaDock server for local protein-protein docking. Nucleic Acids Res. 36, W233–W238 (2008).
44. P. Conway, M. D. Tyka, F. Dimaio, D. E. Konerding, D. Baker, Relaxation of backbone bond geometry improves protein energy landscape modeling. Protein Sci. 23, 47–55 (2014).
45. L. G. Nivón, R. Moretti, D. Baker, A Pareto-optimal refinement method for protein design scaffolds. PLoS One 8, e59004 (2013).
46. H. M. Berman et al., The Protein Data Bank. Nucleic Acids Res. 28, 235–242 (2000).
47. F. Sievers, D. G. Higgins, Clustal Omega for making accurate alignments of many protein sequences. Protein Sci. 27, 135–145 (2018).
48. F. Sievers et al., Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. Mol. Syst. Biol. 7, 539 (2011).
49. P. J. Cock et al., Biopython: Freely available Python tools for computational molecular biology and bioinformatics. Bioinformatics 25, 1422–1423 (2009).
50. M. Waskom et al., Zenodo (mwaskom/seaborn, Version 0.11.1, 2020). http://doi.org/10.5281/zenodo.4379347. Accessed 15 June 2021.